Sai Parenteral’s Limited, a Hyderabad-based diversified pharmaceutical formulations company, brings Sai Parenteral’s IPO to the BSE and NSE mainboard, opening on March 24, 2026, and closing on March 27, 2026, with listing scheduled for April 2, 2026. The IPO size aggregates ₹408.79 crore, comprising a ₹285 crore fresh issue for capacity expansion, working capital, and debt reduction, plus a ₹123.79 crore offer for sale by non-promoter investors, priced at ₹372 – ₹392 per share. Sai Parenteral’s IPO offers exposure to high-margin parenterals growth amid India’s pharma export resurgence.
₹00
₹372
₹
Expert Opinions
Market sentiment for Sai Parenteral’s IPO is constructive, with investors viewing it as a quality play on high-margin sterile injectables and oncology formulations backed by institutional investors. Company strengths include a diversified portfolio across critical care, oncology, and nephrology segments, WHO-GMP and USFDA-compliant manufacturing facilities, strong relationships with domestic hospitals and regulated export markets, and a proven track record of capacity execution. Key risks and challenges involve regulatory compliance in overseas markets, pricing pressure in tenders, dependency on key raw material imports, and intense competition from larger pharma peers.
Valuation Analysis of Financial Year 2025 for Sai Parenteral’s IPO and year indicates Return on Equity (ROE) of 16.82%, ROCE of 28.92%, and Net Asset Value (NAV) of ₹35.98, reflecting efficient capital deployment for a mid-sized formulations player. Long-term investment perspective hinges on successful capacity ramp-up, deeper penetration in regulated markets, and sustained margin expansion from complex injectables.
Investor Considerations
Sai Parenteral’s IPO showcases solid company performance and fundamentals, with consistent revenue growth driven by expanding sterile injectables and oncology formulations sales across domestic and export markets. The Indian pharma sector outlook remains robust, supported by rising hospitalization rates, growing demand for complex generics, and increased focus on regulated market exports. IPO Valuation of Financial Year 2025 for Sai Parenteral’s IPO and year implies a Price to Book Value of 10.89, a PAT Margin of 8.88%, and an EBITDA Margin of 24.18%, reflecting healthy profitability albeit at a premium multiple for a mid-cap formulations peer.
Growth prospects stem from new capacity commissioning, deeper penetration in US and EU regulated markets, and a pipeline of complex injectables. Key risk factors include regulatory inspections, pricing pressure in tenders, raw material volatility, and competition from larger peers. Short-term goals may focus on listing momentum, while long-term investors can target compounding from capacity utilization and product mix upgrades.
FAQs
Sai Parenteral’s IPO Current GMP is ₹00.
Sai Parenteral’s IPO Expected Returns is 0.00%.
Sai Parenteral’s IPO estimated listing price is ₹392.